Swedish Orphan Biovitrum AB (publ) (LON:0MTD)

Market Cap	11.63B +35.4%
Revenue (ttm)	2.28B +8.5%
Net Income	38.53M -87.7%
EPS	0.11 -87.8%
Shares Out	n/a
PE Ratio	301.72
Forward PE	20.87
Dividend	n/a
Ex-Dividend Date	n/a

Volume	187,343
Average Volume	170,013
Open	398.60
Previous Close	403.32
Day's Range	395.40 - 412.60
52-Week Range	242.60 - 410.90
Beta	0.18
RSI	82.75
Earnings Date	Feb 5, 2026

About LON:0MTD

Swedish Orphan Biovitrum AB (publ), a biopharma company, provides medicines in the areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. The company operates through three segments: Haematology, Immunology, and Specialty Care. It offers Alprolix for haemophilia B; ALTUVOCT for the treatment and prophylaxis of bleeding in patients with haemophilia A; Aspaveli/Empaveli for treating adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet for the treatment of immune thrombocy...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1939
• Employees: 1,888
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0MTD

Financial Performance

In 2025, LON:0MTD's revenue was 28.24 billion, an increase of 8.50% compared to the previous year's 26.03 billion. Earnings were 478.00 million, a decrease of -87.70%.

Financial numbers in SEK